<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886704</url>
  </required_header>
  <id_info>
    <org_study_id>477-08</org_study_id>
    <nct_id>NCT00886704</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids, the Omega-3 Index, and Atherosclerosis</brief_title>
  <official_title>Influence of Dietary Omega-3 Fatty Acids in a Convenience Drink (Smartfish) on the Omega-3 Index in Patients With Atherosclerotic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increase in intake of omega-3 fatty acids should increase the Omega-3 Index. Current
      evidence indicates that this may lead to a reduction in risk for sudden cardiac death and
      atherosclerotic diseases like myocardial infarction. The aim of the study is to investigate,
      how supplementing a convenience drink with omega-3 fatty acids influences the Omega-3 Index,
      as compared to an unsupplemented matching convenience drink. Palatability and safety of the
      drink are also to be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Omega-3 Index</measure>
    <time_frame>after eight weeks of intervention</time_frame>
    <description>Percentage of eicosapentaenoic and docosahexaenoic acids in total red cell fatty acids, as determined with a standardized analytical procedure, i.e. the HS-Omega-3 Index. Currently, the target range for the HS-Omega-3 Index has been suggested to be between 8% and 11%. Cardiovascular risk increases at levels below 8%, whereas levels above 11% do not seem to confer further benefit. Values of the HS-Omega-3 Index have been found between 1.5% and 20%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Palatability</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>Palatability assessed as number on a visual analogue scale from 0 - 10, with 0 being the worst and 10 being the best possible outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Convenience drink with EPA and DHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Convenience drink without EPA and DHA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)</intervention_name>
    <description>Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..
Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.
Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.</description>
    <arm_group_label>Convenience drink with EPA and DHA</arm_group_label>
    <arm_group_label>Convenience drink without EPA and DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control convenience drink</intervention_name>
    <description>Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.</description>
    <arm_group_label>Convenience drink without EPA and DHA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must meet the current guideline criteria for atherosclerosis, like coronary,
             peripheral or carotid artery disease, like previous myocardial infarction or acute
             coronary syndrome, coronary revascularization (operation or transluminally), or
             positive angiography or ultrasound.

          2. Age: 30 - 75 years

          3. Low Omega-3 Index (&lt;5%)

          4. Subjects must have adequate fluency in German or English to complete baseline and
             follow-up interviews.

          5. Stable intake of food containing EPA+DHA before and during study

          6. Subjects must be able and willing to give written informed consent, and to comply with
             study procedures.

        Exclusion Criteria:

          1. Subjects for whom the intake of omega-3 fatty acids is mandatory according to recent
             treatment guidelines or who take omega-3 fatty acids supplements on a regular basis.

          2. Patients consuming &gt;2 portions of fatty fish / week

          3. Patients with serious bleeding disorder. Use of platelet inhibitors or anticoagulation
             with a target INR of 2.0 - 3.0 is not an exclusion criterion.

          4. Subjects with any acute and life-threatening condition, such as collapse and shock,
             acute myocardial infarction (last three months), stroke, embolism.

          5. Subjects with significant medical co-morbidity, seriously limiting life expectancy or
             insulin-treated diabetes mellitis or a BMI&gt;30

          6. Allergy/intolerance or history of hypersensitivity to components of study
             intervention, like lactose.

          7. Pregnant subjects - due to any possible teratogenic effects of study nutrition on the
             fetus - and breastfeeding subjects. In addition, women of childbearing potential who
             will not practice a medically accepted method of contraception will be excluded.

          8. Subjects who, in the investigator's judgement, will not likely be able to comply with
             the study protocol or with known drug- or alcohol abuse/dependence in the past 2
             years.

          9. Use of any investigational agents within 30 days prior to t0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens von Schacky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Preventive Cardiology</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Köhler A, Bittner D, Löw A, von Schacky C. Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index. Br J Nutr. 2010 Sep;104(5):729-36. doi: 10.1017/S0007114510001054. Epub 2010 Apr 27.</citation>
    <PMID>20420756</PMID>
  </results_reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <results_first_submitted>June 15, 2011</results_first_submitted>
  <results_first_submitted_qc>August 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2011</results_first_posted>
  <last_update_submitted>September 29, 2011</last_update_submitted>
  <last_update_submitted_qc>September 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clemens von Schacky</name_title>
    <organization>Preventive Cardiology, University of Munich</organization>
  </responsible_party>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>dietary supplementation</keyword>
  <keyword>atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>190 subjects were screened and gave informed consent, and 50 were enrolled.</recruitment_details>
      <pre_assignment_details>The main reason for screen failure (about 95 %) was an omega-3 index &lt; 5.0%. Additional subjects were excluded because of the lack of any evidence for atherosclerotic disease, hospitalisation or lactose intolerance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Convenience Drink With EPA and DHA (Omega-3 Fatty Acids)</title>
        </group>
        <group group_id="P2">
          <title>Convenience Drink Without EPA and DHA</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Convenience Drink With EPA and DHA (Omega-3 Fatty Acids)</title>
        </group>
        <group group_id="B2">
          <title>Convenience Drink Without EPA and DHA</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="6.1"/>
                    <measurement group_id="B2" value="64.5" spread="5.9"/>
                    <measurement group_id="B3" value="64.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Palatability</title>
        <description>Palatability assessed as number on a visual analogue scale from 0 - 10, with 0 being the worst and 10 being the best possible outcome</description>
        <time_frame>at 8 weeks</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Convenience Drink With EPA and DHA</title>
            <description>Palatability</description>
          </group>
          <group group_id="O2">
            <title>Convenience Drink Without EPA and DHA</title>
            <description>Palatability</description>
          </group>
        </group_list>
        <measure>
          <title>Palatability</title>
          <description>Palatability assessed as number on a visual analogue scale from 0 - 10, with 0 being the worst and 10 being the best possible outcome</description>
          <population>Per protocol analysis</population>
          <units>Number on a scale from 0 - 10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.50" spread="1.84"/>
                    <measurement group_id="O2" value="8.39" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Omega-3 Index</title>
        <description>Percentage of eicosapentaenoic and docosahexaenoic acids in total red cell fatty acids, as determined with a standardized analytical procedure, i.e. the HS-Omega-3 Index. Currently, the target range for the HS-Omega-3 Index has been suggested to be between 8% and 11%. Cardiovascular risk increases at levels below 8%, whereas levels above 11% do not seem to confer further benefit. Values of the HS-Omega-3 Index have been found between 1.5% and 20%.</description>
        <time_frame>after eight weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Convenience Drink With EPA and DHA (Omega-3 Fatty Acids)</title>
          </group>
          <group group_id="O2">
            <title>Convenience Drink Without EPA and DHA</title>
          </group>
        </group_list>
        <measure>
          <title>Omega-3 Index</title>
          <description>Percentage of eicosapentaenoic and docosahexaenoic acids in total red cell fatty acids, as determined with a standardized analytical procedure, i.e. the HS-Omega-3 Index. Currently, the target range for the HS-Omega-3 Index has been suggested to be between 8% and 11%. Cardiovascular risk increases at levels below 8%, whereas levels above 11% do not seem to confer further benefit. Values of the HS-Omega-3 Index have been found between 1.5% and 20%.</description>
          <units>% EPA+DHA in total red cell fatty acids</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="0.51"/>
                    <measurement group_id="O2" value="4.71" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Convenience Drink With EPA and DHA (Omega-3 Fatty Acids)</title>
        </group>
        <group group_id="E2">
          <title>Convenience Drink Without EPA and DHA</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single center study, too small to detect rare side effects, 8 week intervention period relatively short.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clemens von Schacky, Head, Preventive Cardiology, University of Munich</name_or_title>
      <organization>Ludwig Maximilians-University Munich</organization>
      <phone>+498951600 ext 2165</phone>
      <email>clemens.vonschacky@med.uni-muenchen.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

